Show simple item record

dc.contributor.authorBousman, CA
dc.contributor.authorMueller, DJ
dc.contributor.authorNg, CH
dc.contributor.authorByron, K
dc.contributor.authorBerk, M
dc.contributor.authorSingh, AB
dc.date.accessioned2020-12-21T03:03:00Z
dc.date.available2020-12-21T03:03:00Z
dc.date.issued2017-01-01
dc.identifier.citationBousman, C. A., Mueller, D. J., Ng, C. H., Byron, K., Berk, M. & Singh, A. B. (2017). Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: a 10-week open-label study. PHARMACOGENETICS AND GENOMICS, 27 (1), pp.1-6. https://doi.org/10.1097/FPC.0000000000000253.
dc.identifier.issn1744-6872
dc.identifier.urihttp://hdl.handle.net/11343/257050
dc.description.abstractBACKGROUND: Pharmacogenetic-based dosing support tools have been developed to personalize antidepressant-prescribing practice. However, the clinical validity of these tools has not been adequately tested, particularly for specific antidepressants. OBJECTIVE: To examine the concordance between the actual dose and a polygene pharmacogenetic predicted dose of desvenlafaxine needed to achieve symptom remission. MATERIALS AND METHODS: A 10-week, open-label, prospective trial of desvenlafaxine among Caucasian adults with major depressive disorder (n=119) was conducted. Dose was clinically adjusted and at the completion of the trial, the clinical dose needed to achieve remission was compared with the predicted dose needed to achieve remission. RESULTS: Among remitters (n=95), there was a strong concordance (Kendall's τ-b=0.84, P=0.0001; Cohen's κ=0.82, P=0.0001) between the actual and the predicted dose need to achieve symptom remission, showing high sensitivity (≥85%), specificity (≥86%), and accuracy (≥89%) of the tool. CONCLUSION: Findings provide initial evidence for the clinical validity of a polygene pharmacogenetic-based tool for desvenlafaxine dosing.
dc.languageEnglish
dc.publisherLIPPINCOTT WILLIAMS & WILKINS
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
dc.titleConcordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: a 10-week open-label study
dc.typeJournal Article
dc.identifier.doi10.1097/FPC.0000000000000253
melbourne.affiliation.departmentPsychiatry
melbourne.affiliation.departmentPathology
melbourne.affiliation.department
melbourne.source.titlePharmacogenetics and Genomics
melbourne.source.volume27
melbourne.source.issue1
melbourne.source.pages1-6
dc.rights.licenseCC BY-NC-ND
melbourne.elementsid1111685
melbourne.contributor.authorBerk, Michael
melbourne.contributor.authorNg, Chee
melbourne.contributor.authorBYRON, KEITH ANDREW
melbourne.contributor.authorBousman, Chad
melbourne.contributor.authorSINGH, AJEET
dc.identifier.eissn1744-6880
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record